Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals

Time from US Food and Drug Administration approval to publication of data for cancer drugs: a... Lammers et al. Blood Cancer Journal (2017) 7:637 DOI 10.1038/s41408-017-0008-9 Blood Cancer Journal CORRESPONDENCE Open Access Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals 1 2 1 1,3,4 Austin Lammers ,RuibinWang , Jeremy Cetnar and Vinay Prasad In 1993, the Omnibus Budget Reconciliation Act required first and subsequent approvals in order to assess for this the Centers for Medicare and Medicaid Services (CMS) to difference. If there were less incentive to seek subsequent pay for off-label cancer drugs if supported by one of the approvals, the average time from publication (used for five compendia, which over time has come to include that compendia inclusion) to approval would be longer. of the National Comprehensive Cancer Network To do this, we ascertained all US FDA hematology and (NCCN) . Estimates suggest that 30% of cancer drug use oncology anti-cancer drug approvals from the FDA in the United States (US) is off-label, amounting to annual website: http://www.fda.gov/Drugs/InformationOnDrugs/ costs of nearly 5 billion dollars in 2010 . Typically, these ApprovedDrugs/ucm279174.htm from 2010 to 2014. We cancer drugs are initially approved for one indication, but once supported by a compendium; http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Blood Cancer Journal Springer Journals

Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals

Loading next page...
 
/lp/springer_journal/time-from-us-food-and-drug-administration-approval-to-publication-of-szgJlNM2CR
Publisher
Springer Journals
Copyright
Copyright © 2017 by The Author(s)
Subject
Biomedicine; Biomedicine, general; Cancer Research; Oncology; Hematology
eISSN
2044-5385
D.O.I.
10.1038/s41408-017-0008-9
Publisher site
See Article on Publisher Site

Abstract

Lammers et al. Blood Cancer Journal (2017) 7:637 DOI 10.1038/s41408-017-0008-9 Blood Cancer Journal CORRESPONDENCE Open Access Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals 1 2 1 1,3,4 Austin Lammers ,RuibinWang , Jeremy Cetnar and Vinay Prasad In 1993, the Omnibus Budget Reconciliation Act required first and subsequent approvals in order to assess for this the Centers for Medicare and Medicaid Services (CMS) to difference. If there were less incentive to seek subsequent pay for off-label cancer drugs if supported by one of the approvals, the average time from publication (used for five compendia, which over time has come to include that compendia inclusion) to approval would be longer. of the National Comprehensive Cancer Network To do this, we ascertained all US FDA hematology and (NCCN) . Estimates suggest that 30% of cancer drug use oncology anti-cancer drug approvals from the FDA in the United States (US) is off-label, amounting to annual website: http://www.fda.gov/Drugs/InformationOnDrugs/ costs of nearly 5 billion dollars in 2010 . Typically, these ApprovedDrugs/ucm279174.htm from 2010 to 2014. We cancer drugs are initially approved for one indication, but once supported by a compendium;

Journal

Blood Cancer JournalSpringer Journals

Published: Nov 30, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off